|Bid||1.6900 x 1400|
|Ask||1.7000 x 900|
|Day's range||1.6500 - 1.8100|
|52-week range||1.4950 - 19.8700|
|Beta (5Y monthly)||1.53|
|PE ratio (TTM)||N/A|
|Earnings date||09 Mar 2022 - 14 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||41.20|
Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?